Internet Drug News.com
Pharmaceutical News & Information; Updated Daily

Research/Regulatory
Medical Dictionary
Clinical Trials In Progress
Clinical Trial Results
SEARCH Medline
Medline Plus  by Topic
Amedeo
Viagra
CDER LIst - (FDA)
Gen Info;Site Dissection

Boiler Plate Patient Info
Advisory Documents
Database Of Ongoing Clinical Trials
New Drug Approvals.org
Dear Doctor Letter Database
Drugs@FDA [gateway]
Drug Approvals Report

Newly filed ANDA's
Product Data Database
Orange Book
Recently Approved Drugs (CenterWatch)
Upcoming Meetings

Medwatch Safety
Recalls/Alerts
NDC Code Directory

Postmarketing Safety Data

Warning Letters
Medwatch Top Pages
Site Map
Pharmaceutical Sales
Diabetes Drugs
Drug Information Databases
Pharmaceutical Sales

Search By Definition

This website is accredited by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here
.

***********
Worth a Click:
- PharmaGossip
- Viagra For Women; Investigative Report
- Patent Docs
- Medical Media & Marketing News
NEW - Farmazia.Net (Spain)
- Canada Pharmacy News
- NewHopeBlog.com
- Drug Wonks
- World Of DTC Marketing.com
¿Your Link Here?
Let's Trade

Pharmaceutical News Harvest (TM)

12/15 Black Thursday at Teva; 25% Staff Cut; "Double-Digit" Number of Factories to Close
Teva axing 14,000 workers, putting R&D and manufacturing facilities on the block in massive restructuring .... Teva is melding together its generics and specialty drug business, integrating two research groups for branded and generic drugs and looking for “synergies” that allow the company to cut deep into R&D .... Endpoints News

12/15 Ten to Watch in 2018
The top 10 prospective blockbuster drug launches slated for 2018 .... There are new advances in HIV and diabetes, and it’s not the least bit unexpected to find that 6 of the 10 are either new cancer therapies or drugs for rare diseases — two fields where the FDA is now squarely behind rapid launches .... Endpoints News

12/15 Pfizer Has an 'Extra' Biosimilar; Deciding What to Do
Pfizer weighs 'strategic options' for newly FDA-approved Remicade biosim, its second .... When Pfizer bought Hospira back in 2015, the drugmaker already had one Remicade biosim in the works; Hospira brought along a second, which is now approved as Inflectra. On 12/14, the FDA blessed Pfizer's internally developed candidate .... Fierce Pharma

12/15 200 Waiting for Yescarta; Patients Dying Waiting for Insurance Clearance
Months After Approval, Breakthrough Cancer Drug Given to Just Five Patients .... Doctors at the cancer centers blame holdups in getting the treatment paid for by Medicare and Medicaid, the two giant U.S. government health programs, as well as some of the U.S.’s largest insurers .... Bloomberg

12/15 Biotechs Getting Better Return on Investment than Traditional Pharma
Bumper crop of new drugs fails to lift big pharma R&D returns .... This decade has seen shrinking profitability in big pharma research labs, with the average internal rate of return (IRR) down sharply from 10.1 percent in 2010 to 3.2 percent this year.... A separate group of four large biotech companies are projected to enjoy an IRR nearly four times higher at 11.9 percent .... Reuters

12/15 If You Like to Curl Up by the Fire with a Stack of Legal Briefs, This Article's Got You Covered
The 2018 biosimilar litigation landscape: A primer .... This year saw numerous new complaints about the law, five new FDA approvals, another biosimilar launch, the first U.S. Supreme Court decision concerning on the topic, and the first jury trial and damages award in a biosimilar case .... BioPharma Dive

12/15 Merck KGaA Pushing Mavenclad (Which Has EU Approval) for US MS Market
Germany's Merck to make new bid to enter U.S. MS pill market .... In early 2011 the U.S. regulator’s concerns put an end to Merck’s development plans for the cladribine pill, now branded as Mavenclad, but Merck later revived efforts by focusing on the most severely affected patients and won approval in Europe in August this year. .... Reuters

12/15 Battle Report from 340B Fight in Congress
Lawmakers battle Trump, PhRMA on discount drug rule .... Lawmakers in both parties are seeking to block the Trump administration’s changes to a Medicare drug discount program, arguing it would have a negative impact on hospitals that serve low-income people .... The Hill

12/15 Gottlieb Posts Policy Goals for 2018; Nicotine Addiction Leads List
Looking ahead: Some of FDA’s major policy goals for 2018 .... FDA serves Americans by delivering on the critical mission of protecting and promoting the public health. The more than 70 actions we have identified, as part of the Fall 2017 Unified Agenda, will help us even better deliver on this mission .... FDA

12/15 Lilly Challenges: Diabetes Competition, Cialis Dropoff
Eli Lilly builds $23B-plus sales forecast on diabetes, cancer launches .... Lilly's 2018 growth will be driven by its newest diabetes drugs—Trulicity, Basaglar and Jardiance—plus plaque psoriasis treatment Taltz and cancer offerings Verzenio, Cyramza, and Lartruvo .... Fierce Pharma


12/15 Internet Drug News Fast Takes:
Vertex licenses its first drug from CRISPR collaboration
BioPharma Dive
Families of dementia patients see positive effect of social robot seal
Reuters
FDA to Pharma Firms: Update or Certify Drug Listings by End of Month
Regulatory Focus
Xepi Receives FDA Approval to Treat Impetigo
PTCommunity
CoolSculpting Was Just FDA-Cleared for Use on Double Chins
Allure



12/14 Hemlibra Will Shake Up the Hemophilia Market, But Shire Expects to Keep Leadership
Shire CEO: Hemophilia will remain a core business .... Sales of hemophilia products make up about a quarter of Shire's global revenues, annualizing to about $3.6 billion per year. Only $800 million or so of those revenues are attributable to sales of the biotech's inhibitor therapies, such as Feiba .... BioPharma Dive

12/14 New Indication for Nucala
First drug approved for rare condition that inflames blood vessels .... Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration as the first remedy to treat adults with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease that leads to inflammation of the blood vessels .... Medical Xpress

12/14 Biosimilar for Remicade Approved
FDA Approves New Pfizer Biosimilar .... The FDA has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab)* for all eligible indications of the reference product .... Company news release

12/14 Yard Sale at Sandoz
Novartis generics arm says may sell or end some products .... Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States .... Reuters

12/14 Fibroids Drug Developer Picked Up at Fire Sale Price
Allergan picks up Repros to boost women's health offerings .... Repros has been developing both an oral and vaginal version of a drug meant to treat uterine fibroids. The oral version has been on clinical hold from the Food and Drug Administration since August 2009 due to safety concerns about elevated levels of liver enzymes .... BioPharma Dive

12/14 Senolytic Medicines (Drugs that Counteract Aging) Raise a Lot of Questions
Why a drug for aging would challenge Washington .... Metformin may not be the strongest potential drug in the anti-aging arsenal, but Barzilai and fellow aging researchers see it as a good stepping stone. It's cheap, available and has been used by humans for decades with a reasonably clean safety record. All that should make it easier for the FDA to say yes to approval as an anti-aging treatment .... Politico

12/14 Stereotactic Radiation, Guided by Detailed Electrocardiography, Eliminates Tachycardia in Trial
A 'Game Changer' for Patients With Irregular Heart Rhythm .... In the three months before they tried the experimental treatment, the five patients together suffered more than 6,500 bouts of tachycardia. It took a month for their hearts to recover from treatment, but in the year afterward the patients collectively had just four episodes of tachycardia, and two did not have any at all .... NY Times

12/14 Walgreens is Keeping Track of How Many Steps You Took Today
Walgreens app makes health tracking easy .... The retailer, which is marketing Striiv, its own branded activity tracker, allows members of the company's Balance Rewards program to also connect through 40 different devices and 27 apps .... Drug Store News

12/14 Promising Advanced Cutaneous Squamous Cell Carcinoma Results
Regeneron, Sanofi Report Positive Top Line Skin Cancer Data .... Cemiplimab is a checkpoint inhibitor targeting PD-1 (programmed death protein 1). The cemiplimab monotherapy study showed an overall response rate (ORR) of 46.3%. .... Zacks

12/14 Botox Chain Gaining Traction; $482 Average Spend per Visit
Woman-Led 'Drybar For Botox' Chain Alchemy 43 Grows -- With Drybar Founders' Backing .... It feels very much like the "beauty lab" Levy bills it as: a physician's assistant, your "alchemist," offers complimentary 3D imaging, showing on a large screen in a private room what your face could look like after a boost from Botox, Dysport, or any of the other fillers on offer. Alchemy 43, like Drybar, offers a membership program to encourage loyalty and frequency. Its $99 monthly subscription has proved a big hit with a younger clientele. .... Zacks


12/14 Internet Drug News Fast Takes:
Ironwood strengthens leadership with two new hires
MM&M
Fears of Israeli Job Cuts at Teva Sparks Call for General Strike
NY Times
Older women should not take hormones to prevent chronic diseases
Reuters
Parkinson's disease progression can be slowed with vigorous exercise, study shows
Chicago Tribune
Medtronic Settles Deceptive Advertising Lawsuit for $12M
Regulatory Focus


12/13 Ascension and Providence St. Joseph Health Hospital Groups Working on Merger; Would Create 191-Hospital Behemoth
Hospital Giants in Talks to Merge to Create Nation's Largest Operator .... A deal would create an entity of unprecedented reach, with 191 hospitals in 27 states and annual revenue of $44.8 billion .... WSJ $$

12/13 "White Coat Marketing" Scheme
Three more drug makers allegedly used nurses to promote medicines .... The documents describe how Gilead Sciences, Amgen, and Bayer Pharmaceuticals hired nurses to talk up treatments to doctors and their patients, an arrangement that purportedly violated federal kickback laws .... Stat $$$$

12/13 Incentive Programs Take Hold in Medicaid
Medical plans dangle gift cards and cash to get patients to take healthy steps .... Medicaid patients who agree to be screened for cancer, attend health-related classes or complete health risk surveys can get gift cards, cash, gym memberships, pedometers or other rewards. They may also get discounts on their out-of-pocket health care costs .... LA Times

12/13 Chemo for Early Breast Cancer Declined from 34.5% to 21.3% Between 2013 and 2015
Fewer women getting chemotherapy for early stage breast cancer .... The latest data suggests physicians are increasingly opting for genomic testing of tumors when a patient's treatment preferences don't align with a doctor's treatment recommendation .... UPI

12/13 "Big Box Pharmacy is a Pressure Cooker" — Results from a National Survey of Pharmacists
The Drug Topics 2017 Pharmacist Salary Survey .... The good news is that the majority of pharmacists got a pay raise in 2017, but it came with a downside: a rise in stress levels .... Drug Topics

12/13 Darzalex Pushing Its Way to the Front of the Line
ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half .... At a median follow-up of 16.5 months, Darzalex, in combination with Takeda's Velcade, melphalan and prednisone, cut the risk of disease progression or death by 50% in newly diagnosed myeloma patients .... Fierce Pharma

12/13 Eight Proposals to Lower Drug Spending: What Are the Chances of Enactment?
Experts Tell Congress How To Cut Drug Prices. We Give You Some Odds. .... The report from the National Academies of Sciences, Engineering and Medicine's committee on drug pricing identifies eight steps to cut drug prices.... It also provides a list of specific "implementation actions" for various federal agencies .... Kaiser Health News

12/13 No Cure for Nonadherence
People Don't Take Their Pills. Only One Thing Seems to Help. .... High-tech approaches and "reminder" packaging don't work well. Reducing prices does. .... NY Times

12/13 Only 4% of Those Who Should Be on PrEP Take the Pill
Many young U.S. men at high risk for HIV do not take anti-HIV pill .... Those at high risk for HIV should ideally take a daily pill to lower their likelihood of infection. So-called pre-exposure prophylaxis cuts the risk of getting HIV from sex by more than 90% .... Reuters

12/13 Only 11% of Golden State Pharmacists Getting into Prescribing Birth Control; Average Service Fee $40–45
Few California retailers offer pharmacist-prescribed birth control, despite law .... Just 11 percent of the state's more than 5,000 community-based retail pharmacies offer birth control. Among those that do, the vast majority (68 percent) charge a fee for the service .... University Of California - Berkeley


12/13 Internet Drug News Fast Takes:
27 Top Cardiologists, Picked By Big Data
Forbes/Matthew Herper
U.S. FDA accepts application for Indivior's new schizophrenia drug
Reuters
FDA Proposal Would Make Clear There's No Gluten in Your Pills
Bloomberg
SEC charges Provectus founding CEO Dees with looting millions for girlfriends' cosmetic surgeries, travel and more
Endpoints
265 Employees Affected as San Diego's Dart NeuroScience Decides to Close Its Doors
Biospace


12/12 Admelog Approved; New Substitute for Humalog
FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog .... Admelog, generally taken just before meals, was approved for use in children older than three and adults with type 1 diabetes, as well as adults with type 2 diabetes .... Reuters

12/12 FDA's OTC Regulations Due for Overhaul
The way over-the-counter drugs are regulated is a mess — and Congress is ready to step in .... The current regulatory process for over-the-counter, or OTC, drugs dates back to 1972, and is based on a simple but flawed assumption that most such products already on the market wouldn't change much over time .... Stat

12/12 Fun Read: Insider Stories on the Discovery and Marketing of Viagra
The Little Blue Pill: An Oral History of Viagra .... [The subjects in one of the first studies] were fitted with what was called a Rigiscan—you can imagine what that does—and given the drug and shown blue movies. At the end of the week, we had to get the drugs back from them, anything that was unused. Some of them would not give the drug back .... Bloomberg

12/12 Antisense Drug Similar to Spinraza Successful in Huntington's disease
'Ground-breaking' new drug gives hope in Huntington's disease .... Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine .... Reuters

12/12 Has the Price of Your Niacor Gone from $35 to $295? Blame Avondale Pharmaceuticals, a Ghost Company from Alabama
US drug company hikes price of everyday vitamin pills by 800% .... Avondale Pharmaceuticals bought the rights to Niacor from Upsher Smith, a division of Japan's Sawai Pharmaceutical, earlier this year. The company also bought the rights to a drug used to treat respiratory ailments, known as SSKI, and increased the price by 2,469 per cent .... The Independent

12/12 Key Day for Graphic Designers: FDA Releases Drug Name Placement Directives
FDA Finalizes Guidance on Promotional Drug Labeling and Ads .... The recommendations pertain to product names in print media promotional labeling and advertisements (e.g., journal ads, detail aids, brochures), audiovisual promotional labeling (e.g., videos shown in a health care provider's office), broadcast advertisements (e.g., television advertisements, radio advertisements) and electronic and computer-based promotions (e.g., internet, social media, emails, CD-ROMs and DVDs). .... Regulatory Focus

12/12 A Dozen New Treatments in the Works for Sickle Cell
Life-Shortening Blood Disease Gets Rush of Gene-Based Research .... Bluebird Bio hopes to cure patients with a single injection of its gene therapy one day. Farther down the road are even more potent and permanent experiments using the gene-editing technology Crispr .... Bloomberg

12/12 Gottlieb's Stepped Approval Idea (for Devices) Drawing Flak
FDA Plans New Medical-Device Approval Processes .... FDA commissioner Scott Gottlieb has called for "progressive," or stepped, approvals of certain devices that would allow them to go to market with initial approvals, with further evidence to assess performance coming later .... WSJ $$

12/12 Pfizer's Cancer Drug Talazoparib Expected to be Fourth PARP Inhibitor — How Will the Market Shake Out
A Cancer-Drug Pricing Experiment Just Got More Interesting .... The PARP inhibitor market is going to be split. The question is to what extent, and whether insurers, pharmacy benefit managers and other payers will use this crowding to lever down drug prices .... Bloomberg Gadfly

12/12 Just 3 FDA Warning Letters in 2017
FDA issues 'record low' number of warnings to drugmakers over misleading ads .... The sharp drop-off in FDA warning letters for lies and misleading statements in ads in recent years, comes amid a 62 percent increase in direct-to-consumer ad spending by pharmaceutical companies .... CNBC


12/12 Internet Drug News Fast Takes:
Medical lab trade group sues over U.S. reimbursement cuts
Reuters
Hospitals are making a fortune on Wall Street
Axios
Lilly Nixes Expansion of Stomach Cancer Drug After Mixed Study Results
xconomy
Amgen's Kyprolis improves overall survival in blood cancer patients
Reuters
Lia Diagnostics gains FDA approval for flushable, biodegradable pregnancy test
Drug Store News

12/11 Fast Takes
Republican tax bill makes big winners of Amgen, Gilead and other drugmakers
Market Watch
Teva Considers 10,000 Job Cuts
Bloomberg
3 Cold-Season Medications That Can Mess With Your Vagina
Health.com
How Eli Lilly's Trajenta, Trulicity, and Basaglar Are Performing
Market Realist
The 2018 pipeline report: Aspiring assets to keep an eye on
MMM Online

12/11 Xarelto Lawsuit Loss Unlikely To Have Huge Impact On JNJ, Bayer
- Something like 20K lawsuits remain on the books
What To Make Of J&J's First Xarelto Lawsuit Loss … first loss of a Xarelto case for the pharma giants, as they won the previous three … 1,500 Xarelto cases pending in the Philadelphia court alone, and over 18,500 cases are pending in federal court. …  out of 20,000 + cases, only 1,500 cases are in Philadelphia, and it remains to be seen how judges in different jurisdictions will rule … [Forbes]

12/11
PHrMA Sues To Block California Drug Price Law
Drug industry group sues to stop California drug price law … seeking to have the law declared unconstitutional on the grounds that it attempts to regulate beyond the state's borders … requires drug manufacturers to give 60 days notice if prices rise more than 16 percent over a two-year period … [Reuters]

12/11 Prescription Drugs May Cost More With Insurance Than Without It
When Buying Prescription Drugs, Some Pay More With Insurance Than Without It … consumers could be overpaying for as many as 1 in 10 prescriptions … Walgreens and was told that he owed $83.94 for a three-month supply on Medicare but Swanljung went online and same drug -- generic Crestor -- for $45.89 … [NY Times]

12/11
Municipalities Save Millions By Encouraging Workers To Buy Foreign Meds Online
- FDA says it's illegal, payers say too bad.
Cities and counties sidestep FDA foreign drug crackdown, saving millions … even though the Food and Drug Administration considers such drug importation to be illegal … "The American people think it's B.S. that you can't buy drugs from Canada or Europe … 90-day supply of the diabetes drug Januvia, imported from Britain, may sell for $83 -- compared with $423 here … [Washington Post]

Artificial Intelligence: will it change the way drugs are discovered?
The Pharmaceutical Journal
Compendium of U.S. Health Systems, 2016
AHRQ
New estimate says 46 million Americans headed to Alzheimer's
NBC News
The Leapfrog Group names its 109 'Top Hospitals'
Advisory Board
Brain scans may reveal most effective anti-drug messages
The Ohio State University


12/7 Drug Spending Growth Takes a Breather
Growth in retail drug spending freefalls along with hepatitis C drug costs .... Retail prescription drug spending hit $328.6 billion in 2016, up 1.3% versus 2015, according to a new analysis by the Office of the Actuary at the Centers for Medicare & Medicaid Services. The figure pales in comparison to 12.4% spending growth in 2014 and 8.9% in 2015 .... Fierce Pharma

12/7 End of an Era; Pfizer to Launch Own Generic for Viagra; No Price Yet for Teva's Product
Viagra goes generic: Pfizer to launch own little white pill .... Pfizer will begin selling the white pill at half the $65-a-pill retail price on Monday, when its patent-protected monopoly ends.... Last year, more than 12 million prescriptions for Viagra and Cialis were filled in the U.S., generating a combined $3 billion in sales.... Prescriptions have dropped more than 20 percent since 2012, as repeated price hikes put the pills out of reach for many men lacking good insurance .... AP/USA Today (autoplay video)

See also:
12/7 The History of Viagra
Sex, Drugs and That Little Blue Pill .... Today, the market has indeed expanded; taken together, Viagra, Cialis and Levitra generate more than $5 billion a year. The market will expand even more once generic Viagra is available. Cialis, too, is going off patent soon, and Lilly is expected to try to get it approved as an over-the-counter drug .... Bloomberg

12/7 Hormone-Based Contraceptives Increase a Woman's Breast Cancer Risk 20%
Study confirms higher breast cancer risk with hormone-based contraception .... Researchers calculated that hormone contraception produced one extra case of breast cancer for every 7,690 women each year. That's a lot of cancers, given that 140 million use hormonal contraception worldwide — or about 13 percent of women ages 15 to 49 .... Reuters

12/7 Deep Dive into CVS-Aetna
The CVS-Aetna Deal: Five Industry and Drug Channel Implications .... A combined Caremark-Aetna PBM will have even more leverage with manufacturers and pharmacies. The Federal Trade Commission will likely consider the PBM component of the transaction to be pro-competitive .... Drug Channels/Adam Fein

12/7 Handy Bundle of Charts from FDA CDER
Cancer R&D tips the scales at the FDA as active INDs climb to record high .... As of the end of November, active INDs hit 7,020 — and that's a 14-year high signifying a steady growth since 2004, when the number was 4,361. .... Endpoints

12/7 Seroquel + Methadone Can Be Fatal
A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster .... From January 2008 to August 2009, AstraZeneca representatives in New York, New Jersey, and Connecticut called on specialists in pain or addiction 800 times and left 4,614 Seroquel XR samples, and the doctors wrote 1,181 new prescriptions, the suit claims .... Bloomberg

12/7 The Aetna-CVS Vision
Aetna wants to create a 'Genius Bar' at CVS, and it could forever change the way Americans access healthcare .... "I think it's less about what the store looks like and more about the offering, and the experience the customer gets is really about a patient-centered medical home model, where we're supporting interaction with the medical community, preparing people for appropriate compliance, preparing them for their visits, setting up appointments, eliminating prior [auths], doing all those other sorts of things to help navigate that system for them" (Aetna CEO Mark Bertolini) .... Business Insider

12/7 Driving Trend Behind This Week's Headlines: Health System Consolidation
UnitedHealth's Deal May Point to Health Care's Future .... The multiplicity of players — drugmakers, doctors, pharmacies, pharmacy benefit managers, insurers, wholesalers and hospitals — means lots of hands trying to grab money from other participants.... Putting multiple health businesses together should mean fewer disputes and reduce attempts by one business to take revenue from another. .... NY Times/Dealbook

12/7 Sales of High-Priced Drugs Rely on Copay Assistance; Fed Crackdown Will Hurt Numbers
Pharma's Helping Hand May Pinch Investors .... Sales of high-price prostate cancer drugs owned by Pfizer and Johnson & Johnson fell sharply earlier this year after a slowdown in charitable contributions led to more giveaways of free drugs .... WSJ $$

12/7 FDA-EMA Proposal on Rare Ped Disease Allows Multiple Products in Same Trial
FDA proposes drug development guidance for rare pediatric diseases .... The FDA has issued draft guidance to simplify the procedure of developing drugs for rare pediatric disorders, such as Gaucher's disease, by eliminating the need for certain trials and minimizing patient enrollment .... Reuters


12/7 Internet Drug News Fast Takes:
Roche's Avastin wins FDA nod to treat glioblastoma
Marketwatch
Amazon's license stumble in Maine displays inexperience in pharmacy
CNBC
GSK's Shingrix proven effective in immune-compromised patient populations
Drug Store News
Disruption of the Year: Long-Acting Hemophilia Drugs
Biopharma Dive
SoCal's Avanir Scrutinized for Nudexta Prescriber Support Program, Will Lay Off 73 Employees in 2018
Biospace


12/6 Larry Merlo Turned Around Caremark; Can He Make Aetna–CVS Work?
CVS Boss Larry Merlo's Path From Corner Pharmacy to C-Suite .... His low-key demeanor belies a willingness to take risks and make jolting changes. His decision in 2014 to halt sales of all tobacco products cost the company $2 billion a year in revenue. Mr. Merlo said the move was needed for CVS to become a significant competitor in the health-care system .... WSJ $$

See also:
12/6 Nice Payday
Aetna's Outgoing CEO Set to Reap About $500 Million if CVS Deal Closes .... Mark Bertolini to benefit from up to $85 million of exit pay plus existing rights and stock that are worth more because of the deal .... WSJ $$

12/6 'Breakthrough' and 'Fast-Track' Programs Have Sped Approvals Significantly
FDA's program to speed up drug approval shaved nearly a year off the process .... Of 174 drugs and biologic therapies approved between January 2012 and December 2016, 105 (or 60%) traversed the FDA evaluation process with one of four designations aimed at speeding the path to approval. The 69 candidate medications that had no such hurry-up designations took between 6.5 and 10 years to proceed from the start of human trials to FDA approval, with a midpoint of eight years .... LA Times

12/6 Ozempic (semaglutide) GLP-1 Analog Approved; $676 per Prescription
FDA approves Novo Nordisk diabetes drug Ozempic .... Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza. Novo Nordisk is also developing an oral form of semaglutide .... Reuters

12/6 Maker to Fork Over $28 Million in Xarelto Case; First Loss in Count
Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit .... The trial was the first of roughly 1,400 Xarelto cases pending in the Philadelphia court. More than 18,500 cases are pending in federal court .... Reuters

12/6 AbbVie: The World's Bestselling Drug and a Deep Bench Too
Pharma of the Year: AbbVie .... AbbVie expects Humira to hit $21 billion in revenues in 2020.... Competition isn't expected for Humira in Europe until 2018 and isn't likely to enter the U.S. market until 2023 .... Biopharma Dive

12/6 Pfizer the Smartest Company in the DJIA, Followed by Boeing, Apple, Visa and Johnson & Johnson
Pfizer tops Dow's intellectual heap, with J&J and Merck close behind: study .... The organization uses an accounting-based method to calculate the value of intangible assets, such as patents, brands and proprietary data, and then determines that percentage of market value as an index to rank the companies .... Fierce Pharma

12/6 Meet Laurus Labs, Whose Anti-Retroviral APIs Have Driven Costs Down to $100/Person/Year
This Company Is About to Flood the U.S. With Cheap HIV Drugs .... Among the coconut plantations and beaches of South India, a factory the size of 35 football fields is preparing to churn out billions of generic pills for HIV patients and flood the U.S. market with the low-cost copycat medicines .... Bloomberg

12/6 Pharmacists (Rather than Nurses or Doctors) Do a Better of Getting Medication Histories in the ER
When Pharmacy Experts Take Medical Histories, Medication Errors Drop 80 Percent .... Errors in medication histories can lead physicians to order the wrong drug, dose or frequency. Electronic health records help, but not enough, because errors that are introduced into the record by individuals with varying levels of knowledge can become 'hardwired' and used for prescribing medications that can cause harm .... Science 2.0

12/6 Depomed Layoffs; Asset Sales
Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs .... Less than three years after shelling out $1.05 billion to acquire Nucynta ER and XR from Johnson & Johnson, the California drugmaker has licensed the meds to Collegium Pharmaceutical for just $10 million upfront. For the first four years, Depomed will receive a minimum of $135 million in royalties each year .... Fierce Pharma


12/6 Internet Drug News Fast Takes:
Hospitals find asthma hot spots more profitable to neglect than fix
Washington Post
27 Top Breast Cancer Oncologists, Picked By Big Data
Forbes/Matthew Herper
Biotech hedge fund titan Sam Isaly harassed, demeaned women for years, former employees say
Stat + $$$
Nearly 60 percent of top health insurers' revenue comes from Medicare and Medicaid
CNBC
GroupM unveils upbeat global adspend forecast for 2018
MM&M

Site Map | Privacy Policy | Contact Webmaster
Site Mission Statement, Intended Audience, Editorial Policy, Advertising Policy
This Page Last Updated 12/12/2017

If your intellectual property being infringe
e-mail the webmaster and we will fix it. 

The information on this site is not meant as medical advice.  If you have any medical questions please consult your medical doctor or similar medical practitioner. 

The information contained on this web site is for your information only.  Never take a drug without a doctor's prescription - only an idiot does that.   
Do NOT give yourself any drug unless it has been prescribed for you by a doctor.

Do NOT start or stop taking a medicine based on information you read here or any other internet web site because this could cause you to become seriously ill or die or worse even.

Sincerely,

Corey Nahman Licensed Pharmacist (State Of NY; Lic #035512)

*****************************************
We subscribe to The HONcode of  online conduct:

1.  Qualification of author(s)
This site is published and webmastered by Corey Nahman, Registered pharmacist in the Sate of New York.
2.  Complementarity
Let it be known that the information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.
3.  Privacy.
We respect the privacy of the users of this site.  Please see our plain English privacy policy.
4. Attribution
At all times, the information on this site shall be footnoted with the source(s) of published information, date and medical and health pages provided.
5.  Justifiability
This site shall at all times back up claims relating to benefits and performance.
6  Transparency
This site shall at all times use accessible presentation, you can e-mail the publisher of this site at his personal e-mail address at any time.
7.  Financial disclosure
This site is supported by click advertisements, banner advertisements and affiliate arrangements.  All ads are properly labeled as such.  If you have any questions regarding how we make money please e-mail the webmaster with your questions.  All advertisements shall be clearly distinguished from content.

Badea, Badea, Badea,
That's All Folks!